β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity. In Vitro: β-Amyloid (31-35) is a functional cytotoxic domain of Aβ peptide. β-Amyloid (31-35) increases the phosphorylation of biotinylated Aβ(1-40), enhances CDK-1 activity, and also inhibits binding of Aβ to cyclin B1. β-Amyloid (31-35) is cytotoxic, and such an effect can be inhibited by olomoucine in differentiated human teratocarcinoma cell line, Ntera 2/cl-D1 (NT-2) neurons^[1]. β-Amyloid (31-35) shows cytotoxic effect on cerebellar granule cells (CGC). β-Amyloid (31-35) also increases caspase-3 activity in a time-dependent manner (4-24 h) at 40 μM^[2].